Functional inclusion bodies produced in bacteria as naturally occurring nanopills for advanced cell therapies.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22410789.
- Also identified by DOI 10.1002/adma.201104330.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inclusion bodies (50-500 nm in diameter) produced in recombinant bacteria can be engineered to contain functional proteins with therapeutic potential. Upon exposure, these protein particles are efficiently internalized by mammalian cells and promote recovery from diverse stresses. Being fully biocompatible, inclusion bodies are a novel platform, as tailored nanopills, for sustained drug release in advanced cell therapies.
Medical subject headings
- Delayed-Action Preparations
- Escherichia coli
- Inclusion Bodies
- Recombinant Proteins